Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GERN NASDAQ:IRWD NASDAQ:LXRX NASDAQ:SABS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGERNGeron$1.17-3.3%$1.46$1.04▼$2.01$776.24M0.612.93 million shs9.50 million shsIRWDIronwood Pharmaceuticals$3.31-2.6%$3.81$0.57▼$5.78$554.40M0.252.33 million shs1.33 million shsLXRXLexicon Pharmaceuticals$1.91+0.5%$1.88$0.64▼$2.53$843.97M1.073.10 million shs1.76 million shsSABSSAB Biotherapeutics$3.38-2.6%$3.75$1.60▼$6.60$265.33M0.54857,809 shs351,621 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGERNGeron+4.31%-3.20%-26.67%-20.92%-21.43%IRWDIronwood Pharmaceuticals+4.78%-5.69%-27.30%-2.72%+463.86%LXRXLexicon Pharmaceuticals+2.70%-14.03%+15.15%+11.11%+187.40%SABSSAB Biotherapeutics+3.27%-2.80%-5.71%-8.44%+85.81%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGERNGeron$1.17-3.3%$1.46$1.04▼$2.01$776.24M0.612.93 million shs9.50 million shsIRWDIronwood Pharmaceuticals$3.31-2.6%$3.81$0.57▼$5.78$554.40M0.252.33 million shs1.33 million shsLXRXLexicon Pharmaceuticals$1.91+0.5%$1.88$0.64▼$2.53$843.97M1.073.10 million shs1.76 million shsSABSSAB Biotherapeutics$3.38-2.6%$3.75$1.60▼$6.60$265.33M0.54857,809 shs351,621 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGERNGeron+4.31%-3.20%-26.67%-20.92%-21.43%IRWDIronwood Pharmaceuticals+4.78%-5.69%-27.30%-2.72%+463.86%LXRXLexicon Pharmaceuticals+2.70%-14.03%+15.15%+11.11%+187.40%SABSSAB Biotherapeutics+3.27%-2.80%-5.71%-8.44%+85.81%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGERNGeron 2.00Hold$2.50113.68% UpsideIRWDIronwood Pharmaceuticals 2.43Hold$6.2388.32% UpsideLXRXLexicon Pharmaceuticals 2.33Hold$4.55138.22% UpsideSABSSAB Biotherapeutics 2.80Moderate Buy$11.00225.44% UpsideCurrent Analyst Ratings BreakdownLatest SABS, LXRX, GERN, and IRWD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/26/2026GERNGeron Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/22/2026SABSSAB Biotherapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$11.005/20/2026SABSSAB Biotherapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$11.005/20/2026SABSSAB Biotherapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$11.005/12/2026SABSSAB Biotherapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$7.00 ➝ $10.005/11/2026LXRXLexicon Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$2.30 ➝ $3.105/11/2026SABSSAB Biotherapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/11/2026SABSSAB Biotherapeutics Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.004/27/2026GERNGeron Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/27/2026IRWDIronwood Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)4/10/2026SABSSAB Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGERNGeron$183.88M4.08N/AN/A$0.35 per share3.34IRWDIronwood Pharmaceuticals$296.15M1.82$0.25 per share13.21($1.61) per share-2.06LXRXLexicon Pharmaceuticals$49.80M17.04N/AN/A$0.30 per share6.37SABSSAB Biotherapeutics$1.32M195.78$0.33 per share10.15$3.18 per share1.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGERNGeron-$83.50M-$0.11N/A11.70N/A-35.48%-23.31%-10.08%8/5/2026 (Estimated)IRWDIronwood Pharmaceuticals$24.02M$0.605.52N/AN/A28.26%-39.65%26.54%8/6/2026 (Estimated)LXRXLexicon Pharmaceuticals-$50.34M-$0.07N/AN/AN/A-37.46%-18.64%-11.79%8/5/2026 (Estimated)SABSSAB Biotherapeutics$13.27M-$2.11N/AN/AN/AN/A-0.29%-0.25%8/6/2026 (Estimated)Latest SABS, LXRX, GERN, and IRWD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026SABSSAB Biotherapeutics-$0.20-$0.35-$0.15-$0.35$0.13 millionN/A5/7/2026Q1 2026IRWDIronwood Pharmaceuticals$0.2467$0.24-$0.0067$0.24$92.11 million$106.51 million5/7/2026Q1 2026LXRXLexicon Pharmaceuticals-$0.04-$0.0026+$0.0374N/A$9.79 million$21.10 million5/6/2026Q1 2026GERNGeron-$0.03-$0.01+$0.02-$0.01$50.59 million$51.84 million3/9/2026Q4 2025SABSSAB Biotherapeutics-$0.16-$0.46-$0.30-$0.46N/AN/A3/5/2026Q4 2025LXRXLexicon Pharmaceuticals-$0.07-$0.04+$0.03-$0.04$3.14 million$5.49 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGERNGeronN/AN/AN/AN/AN/AIRWDIronwood PharmaceuticalsN/AN/AN/AN/AN/ALXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/ASABSSAB BiotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGERNGeron0.526.784.96IRWDIronwood PharmaceuticalsN/A1.411.41LXRXLexicon Pharmaceuticals0.2418.8018.77SABSSAB Biotherapeutics0.0111.4511.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGERNGeron73.71%IRWDIronwood PharmaceuticalsN/ALXRXLexicon Pharmaceuticals74.70%SABSSAB Biotherapeutics7.82%Insider OwnershipCompanyInsider OwnershipGERNGeron1.71%IRWDIronwood Pharmaceuticals9.30%LXRXLexicon Pharmaceuticals14.00%SABSSAB Biotherapeutics25.06%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGERNGeron70641.52 million630.55 millionOptionableIRWDIronwood Pharmaceuticals220163.06 million147.89 millionOptionableLXRXLexicon Pharmaceuticals140444.20 million382.01 millionOptionableSABSSAB Biotherapeutics14076.46 million57.30 millionNot OptionableSABS, LXRX, GERN, and IRWD HeadlinesRecent News About These CompaniesSAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual MeetingMay 29, 2026 | finance.yahoo.comSAB BIO to Present Data on SAB-142 at The American Diabetes Association's 2026 Scientific Sessions and FOCIS 2026 Annual MeetingMay 29, 2026 | globenewswire.comSAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Average Recommendation of "Moderate Buy" from BrokeragesMay 28, 2026 | americanbankingnews.comCitigroup initiates coverage of SAB Biotherapeutics (SABS) with buy recommendationMay 23, 2026 | msn.comWhy SAB Biotherapeutics, Inc.’s (SABS) Stock Is Up 7.01%May 21, 2026 | aaii.comASAB Biotherapeutics Inc SABSMay 20, 2026 | morningstar.comMJefferies initiates coverage of SAB Biotherapeutics (SABS) with buy recommendationMay 20, 2026 | msn.comSAB Biotherapeutics Signs Manufacturing Pact for SAB-142May 16, 2026 | theglobeandmail.comWe Think SAB Biotherapeutics (NASDAQ:SABS) Needs To Drive Business Growth CarefullyMay 16, 2026 | finance.yahoo.comSAB Biotherapeutics Inc (SABS) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Rising ...May 12, 2026 | finance.yahoo.comSAB Biotherapeutics Q1 Earnings Call HighlightsMay 12, 2026 | marketbeat.comSAB BIO Reports Q1 2026 Financial Results and Recent Business HighlightsMay 12, 2026 | globenewswire.comSAB Biotherapeutics (NASDAQ:SABS) Given Buy Rating at Rodman & RenshawMay 11, 2026 | marketbeat.comSAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ETMay 5, 2026 | globenewswire.comEmergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB ...April 29, 2026 | caledonianrecord.comCSAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026April 22, 2026 | globenewswire.comSAB Biotherapeutics Looks Undervalued If SAB-142 Delivers In Type 1 DiabetesApril 15, 2026 | seekingalpha.comSAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society CongressApril 15, 2026 | markets.businessinsider.comSAB Biotherapeutics closes $85 million public offeringMarch 20, 2026 | thepharmaletter.comTSAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded WarrantsMarch 19, 2026 | globenewswire.comSAB Biotherapeutics Launches Major Equity Financing OfferingMarch 19, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSABS, LXRX, GERN, and IRWD Company DescriptionsGeron NASDAQ:GERN$1.17 -0.04 (-3.31%) Closing price 04:00 PM EasternExtended Trading$1.18 +0.01 (+0.43%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Ironwood Pharmaceuticals NASDAQ:IRWD$3.31 -0.09 (-2.65%) Closing price 04:00 PM EasternExtended Trading$3.37 +0.06 (+1.84%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.Lexicon Pharmaceuticals NASDAQ:LXRX$1.91 +0.01 (+0.53%) Closing price 04:00 PM EasternExtended Trading$1.90 -0.01 (-0.79%) As of 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.SAB Biotherapeutics NASDAQ:SABS$3.38 -0.09 (-2.59%) Closing price 04:00 PM EasternExtended Trading$3.31 -0.07 (-2.07%) As of 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
